Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors
Latest Information Update: 31 Mar 2023
At a glance
- Drugs CP 870893 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 29 Aug 2014 New trial record